Compounded semaglutide in Texas: what GLP-1 patients need to know after the FDA ruling

What happened to compounded semaglutide in 2025?

The FDA removed semaglutide (the active ingredient in Ozempic and Wegovy) from its drug shortage list in February 2025. Under federal law, once a drug is removed from the shortage list, 503A compounding pharmacies — those that fill prescriptions for individual patients — must stop producing compounded versions unless the patient has a specific documented allergy or intolerance to an inactive ingredient in the commercial product. This change does not affect commercially manufactured Ozempic or Wegovy, which remain available through standard pharmacy channels with a valid prescription.

Tirzepatide (the active ingredient in Mounjaro and Zepbound) followed in May 2025 when it was also removed from the FDA shortage list, triggering similar restrictions for compounded tirzepatide.

Can Texas patients still access compounded semaglutide?

Most Texas patients cannot access compounded semaglutide from a standard compounding pharmacy after the shortage-list removal unless they qualify for an exemption based on a documented allergy or clinical need that commercial products cannot meet. 503B outsourcing facilities — which produce larger batches for healthcare facilities — operate under a different regulatory framework and may have additional latitude depending on specific circumstances, but access through that channel is not the same as a standard patient prescription.

Patients who were on compounded semaglutide programs through telehealth clinics should have received notice from their provider about the transition. If you have not heard from your provider, that conversation should happen before your next refill cycle.

What are the options for Texas patients who were on compounded GLP-1 programs?

For patients who need to continue GLP-1 therapy after the compounding change, the clinically straightforward path is transitioning to a commercially available branded product — Wegovy for weight management or Ozempic for type 2 diabetes management with weight benefit — with a prescription from a licensed provider.

The transition involves a conversation with your provider about:

• Your current dose and how it maps to commercial dosing options
• Insurance coverage or patient assistance programs for the branded product (Novo Nordisk offers a savings card program for commercial insurance patients; income-based assistance is available through its patient assistance program)
• Whether tirzepatide (Mounjaro or Zepbound) is a clinically appropriate alternative based on your metabolic profile and treatment goals

A telehealth visit is sufficient to evaluate your current response, adjust your plan, and issue a new prescription for the commercially available product — no in-person appointment required.

Does the FDA change affect GLP-1 access for new patients in Texas?

No. The FDA shortage-list removal affects compounded versions of semaglutide and tirzepatide. Commercial Ozempic, Wegovy, Mounjaro, and Zepbound remain available with a valid prescription from a licensed prescriber. New patients starting a medically supervised GLP-1 program in 2025 and beyond work with a licensed provider, receive a commercial prescription, and fill it at a standard pharmacy or through specialty pharmacy channels.

The clinical process — provider evaluation, metabolic labs, BMI and comorbidity assessment, shared decision-making on which GLP-1 is appropriate — is the same as it was before the compounding change.

What should Texas patients do if they were taking compounded semaglutide?

If your current supply is running low or you are approaching a refill, schedule a telehealth visit with a licensed Texas provider before the gap occurs. Do not wait until your supply runs out to address the transition. A brief virtual visit allows your provider to review your current progress, assess whether the commercial product at an equivalent dose is appropriate, and submit a new prescription to your pharmacy of choice.

According to a 2021 clinical trial published in The New England Journal of Medicine (STEP 1, Wilding et al.), patients on a 2.4 mg weekly dose of semaglutide achieved a mean body weight reduction of 14.9% over 68 weeks. That clinical benefit is achievable with the commercially available product — the compounding change does not change the evidence base for GLP-1 therapy.

Patients managing weight loss through a supervised GLP-1 program can schedule a transition visit at health.copergrine.com. Copergrine Health & Wellness provides evaluation, prescription management, and ongoing GLP-1 follow-up entirely through telehealth for Texas patients.

FAQ

Is compounded semaglutide still legal in Texas?

After the FDA removed semaglutide from the drug shortage list in February 2025, compounding pharmacies that fill individual patient prescriptions (503A pharmacies) must stop producing compounded semaglutide unless the patient has a documented allergy or intolerance to an inactive ingredient in the commercial product. Access through standard compounding channels is significantly restricted.

Is tirzepatide affected by the same FDA ruling?

Yes. The FDA removed tirzepatide from its shortage list in May 2025, triggering similar restrictions on compounded tirzepatide from 503A pharmacies. Commercially available Mounjaro and Zepbound remain available with a valid prescription.

Can a Texas telehealth provider still prescribe GLP-1 medications?

Yes. A licensed Texas telehealth provider can evaluate patients, assess appropriateness for GLP-1 therapy, and prescribe commercially available semaglutide or tirzepatide products. The restriction applies to compounded versions, not to the FDA-approved commercial products.

CTA: Managing a GLP-1 program or navigating the transition? Book a telehealth visit with a Texas provider at Copergrine Health & Wellness →